Drug therapy in kidney disease
Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers
Pharmacokinetics of a novel agent, R667, in patients with emphysema
Pharmacokinetics of desloratadine in children between 2 and 11 years of age
Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers
The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension
Assessment of renal function in clinical practice at the bedside of burn patients
Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials
Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects
Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist
Quality of requests for serum digoxin concentrations
Palatability of angiotensin II antagonists among nephropathic children
Poor correlation between 6β-hydroxycortisol
Authors' response
Reverse transcriptase inhibitors in HIV/AIDS therapy
Erratum